Clinical Trial Update: Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients [NA]

View source ↗

Summary

A clinical trial evaluating chidamide in combination with Brentuximab Vedotin for CD30-positive peripheral T-cell lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cd30-positive Peripheral T-cell Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)
• Chidamide (chidamide)

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: CD30+ Peripheral T-cell Lymphoma | NA | Status: RECRUITING